Skip to main content

Summary

for people ages 2–17 (full criteria)
at Oakland, California and other locations
study started
estimated completion:

Description

Summary

This is a randomized, open-label, multicenter, two arm, phase II study to evaluate treatment compliance and change in serum ferritin of a deferasirox granule formulation and a deferasirox DT formulation in children and adolescents aged ≥ 2 and < 18 years at enrollment with any transfusion-dependent anemia requiring chelation therapy due to iron overload, to demonstrate the effect of improved compliance on iron burden. Randomization will be stratified by age groups (2 to <10 years, 10 to <18 years) and prior iron chelation therapy (Yes/ No). There will be two study phases which include a 1 year core phase where patients will be randomized to a 48 week treatment period to either Deferasirox DT or granules, and an optional extension phase where all patients will receive the granules up to 5 years. Patients who demonstrated benefit to granules or DT in the core phase, and/or express the wish to continue in the optional extension phase on granules, will be offered this possibility until there is local access to the new formulation (granules or FCT) or up to 5 years, whichever occurs first.

Official Title

A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload

Keywords

Transfusion-dependent Anemia New formulation, deferasirox, chelation, iron overload, compliance, satisfaction, palatability, PRO, PK, safety, PK/PD, ICL670 Iron Overload Anemia Deferasirox

Eligibility

You can join if…

Open to people ages 2–17

  • Written informed consent/assent before any study-specific procedures. Consent will be obtained from parent(s) or legal guardians. Investigators will also obtain assent of patients according to local guidelines.
  • Male and female children and adolescents aged ≥ 2 and < 18 years. [France: Male and female children and adolescent aged ≥ 2 and < 18 years old, however children aged ≥ 2 and ≤ 6years can be enrolled only when deferoxamine treatment is contraindicated or inadequate in these patients as per investigator decision. Applicable to core phase only. Once in the core phase patients can turn 18 years and still be considered eligible, also for participation in the optional extension phase.
  • Any transfusion-dependent anemia associated with iron overload requiring iron chelation therapy and with a history of transfusion of approximately 20 PRBC units and a treatment goal to reduce iron burden (300mL PRBC = 1 unit in adults whereas 4 ml/kg PRBC is considered 1 unit for children).
  • Serum ferritin > 1000 ng/mL, measured at screening Visit 1 and screening Visit 2 (the mean value will be used for eligibility criteria).
  • Patient has to have participated and completed the 48 weeks core phase treatment as per protocol (For optional extension phase eligibility only).
  • Patient needs to meet all the eligibility criteria (inclusion and exclusion) as defined in the core phase at Visit 17 (For optional extension phase eligibility only).

You CAN'T join if...

  • Creatinine clearance below the contraindication limit in the locally approved prescribing information (using Schwartz formula) at screening visit 1 or screening visit 2.
  • Serum creatinine > 1.5 xULN at screening measured at screening Visit 1 and or screening Visit 2
  • ALT and/or AST > 3.0 x ULN at screening visit 1 or screening visit 2.
  • (Criterion no longer applicable, removed as part of Amendment 1): Prior iron chelation therapy.
  • Liver disease with severity of Child-Pugh class B or C.
  • Significant proteinuria as indicated by a urinary protein/creatinine ratio > 0.5 mg/mg in a second morning urine sample at screening Visit 1 or screening Visit 2.
  • Patients with significant impaired gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral deferasirox (e.g. ulcerative diseases,uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).

Other protocol-defined Inclusion/Exclusion may apply.

Locations

  • Children's Hospital Oakland Onc Dept accepting new patients
    Oakland, California, 94609, United States
  • Texas Children's Hospital Oncology Department accepting new patients
    Houston, Texas, 77030, United States
  • St. Jude Children's Research Hospital Memphis St Jude accepting new patients
    Memphis, Tennessee, 38105, United States
  • Lurie Children's Hospital of Chicago Onc Dept accepting new patients
    Chicago, Illinois, 60611, United States
  • Vanderbilt Univeristy Vanderbilt University Medical accepting new patients
    Nashville, Tennessee, 37232, United States
  • Children's Healthcare of Atlanta Onc Dept accepting new patients
    Atlanta, Georgia, 30342, United States
  • Medical University of South Carolina Medical Uni of South Carolina accepting new patients
    Charleston, South Carolina, 29425, United States
  • Children's Hospital of Philadelphia Onc. Dept accepting new patients
    Philadelphia, Pennsylvania, 19104-4399, United States
  • Weill Cornell Medical College SC - accepting new patients
    New York, New York, 10021, United States
  • Children's Hospital at Montefiore accepting new patients
    The Bronx, New York, 10467, United States
  • Novartis Investigative Site accepting new patients
    Panama City, Republica de Panama, Panama
  • Novartis Investigative Site accepting new patients
    Medellin, Colombia
  • Novartis Investigative Site accepting new patients
    Moskow, 117198, Russian Federation
  • Novartis Investigative Site accepting new patients
    Brussel, 1200, Belgium
  • Novartis Investigative Site accepting new patients
    Edegem, 2650, Belgium
  • Novartis Investigative Site accepting new patients
    Créteil, 94000, France
  • Novartis Investigative Site accepting new patients
    Paris, 75015, France
  • Novartis Investigative Site accepting new patients
    Budapest, 1094, Hungary
  • Novartis Investigative Site accepting new patients
    Debrecen, 4032, Hungary
  • Novartis Investigative Site accepting new patients
    Genova, GE, 16128, Italy
  • Novartis Investigative Site accepting new patients
    Palermo, PA, 90127, Italy
  • Novartis Investigative Site accepting new patients
    Palermo, PA, 90146, Italy
  • Novartis Investigative Site completed
    Orbassano, TO, 10043, Italy
  • Novartis Investigative Site accepting new patients
    Napoli, 80132, Italy
  • Novartis Investigative Site accepting new patients
    Plovdiv, 4002, Bulgaria
  • Novartis Investigative Site accepting new patients
    Sofia, 1527, Bulgaria
  • Novartis Investigative Site accepting new patients
    Varna, 9010, Bulgaria
  • Novartis Investigative Site accepting new patients
    Tunis, 1006, Tunisia
  • Novartis Investigative Site accepting new patients
    Adana, 01330, Turkey
  • Novartis Investigative Site accepting new patients
    Ankara, 06100, Turkey
  • Novartis Investigative Site accepting new patients
    Izmir, 35040, Turkey
  • Novartis Investigative Site accepting new patients
    Quezon City, 1100, Philippines
  • Novartis Investigative Site accepting new patients
    Hazmiyeh, Beirut, PO Box 213, Lebanon
  • Novartis Investigative Site accepting new patients
    Bangkok noi, Bangkok, 10700, Thailand
  • Novartis Investigative Site accepting new patients
    Muang, Chiangmai, 50200, Thailand
  • Novartis Investigative Site accepting new patients
    Kuching, Sarawak, 93586, Malaysia
  • Novartis Investigative Site accepting new patients
    Kuala Lumpur, 50589, Malaysia
  • Novartis Investigative Site accepting new patients
    Pulau Pinang, 10990, Malaysia
  • Novartis Investigative Site accepting new patients
    Muscat, 123, Oman

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Novartis Pharmaceuticals
ID
NCT02435212
Phase
Phase 2
Study Type
Interventional
Last Updated
July 27, 2017
I’m interested in this study!